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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the benefits and harms of glucocorticosteroids in people with alcoholic hepatitis.
B A C K G R O U N D
Description of the condition
The term ’alcoholic hepatitis’ was used for the first time in a paper
by Beckett and colleagues in 1961 (Beckett 1961), but clinical
jaundice after excessive ethanol consumption was reported in the
literature long before that (Gerber 1973). Most probably, these
reports represented people with alcoholic hepatitis (Mendenhall
1984; Jensen 1994).
Alcoholic hepatitis is a serious formof alcoholic liver disease (injury
of the liver due to excessive alcohol consumption) (WHO 2010).
Alcoholic hepatitis is synonymous with alcoholic steatohepatitis
(Stickel 2013).
The first stage of liver damage in alcoholic hepatitis is usually re-
versible if people abstain from drinking, but the risk of progres-
sion to fibrosis and cirrhosis increases with resumed drinking (Ellis
2012). The accumulation of fat in the hepatocytes causes disrup-
tion of the mitochondrial beta-oxidation of fatty acids, accumula-
tion of lipotoxic metabolites, and release of reactive oxygen species
(Lieber 1999; Wu 1999; Petrasek 2013). Lipotoxic metabolites
and reactive oxygen species lead to cell death and liver inflamma-
tion (Wu 1999; Petrasek 2013). Alcoholic hepatitis can be asymp-
tomatic or symptomatic, and the risk of whether or not cirrhosis
will develop in a person varies (WHO 2013). Alcoholic hepatitis
is a histological form of alcoholic liver disease, characterised by
steatosis (the earliest stage of alcoholic liver damage) and necroin-
flammation (EASL 2012). Only 10% to 35% of heavy drinkers
(defined as consumption of more than 60 g to 80 g of alcohol per
day in men and more than 20 g of alcohol per day in women),
with evidence of fatty liver, are expected to develop hepatitis. With
time, alcoholic hepatitis causes liver fibrosis, liver cirrhosis, and
primary liver cancer (hepatocellular carcinoma) (WHO 2013).
Severe alcoholic hepatitis may be characterised by clinically clear
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signs of jaundice, coagulopathy, liver decompensation with as-
cites, portal hypertension, variceal bleeding, hepatorenal syn-
drome, hepatic encephalopathy, systemic inflammatory response
syndrome, or sepsis (Becker 1996; EASL 2012). Typically, alco-
holic hepatitis presents in people aged between 40 and 50 years.
Among the risk factors of developing severe alcoholic hepatitis
are female sex, Hispanic ethnicity, various types of alcohol, binge
drinking, poor nutrition, and obesity (WHO 2010). Several com-
posite prognostic scores exist to distinguish people with poor prog-
nosis from people who can become abstinent, instituting sup-
portive care, until recovery is achieved. These scores, designed
to predict mortality, include the Maddrey’s discriminant function
(Maddrey 1978); the model of end-stage liver disease (MELD)
score (Dunn 2005); the Glasgow alcoholic hepatitis score (Forrest
2005); and the age, bilirubin, international normalised ratio, cre-
atinine (ABIC) score (Dominguez 2008).
The Maddrey’s discriminant function is the most frequently used
score in severe alcoholic hepatitis to identify people in potential
need of glucocorticosteroids. The one-month survival of people
with alcoholic hepatitis and with Maddrey’s score higher than 32
varies between 50% and 65% (Carithers 1989; Phillips 2006).
The Lille Model is the only validated model so far to assess glu-
cocorticosteroid response and is highly predictive of death at six
months (P value < 0.000001) in people with severe alcoholic hep-
atitis (Louvet 2007) (www.lillemodel.com). A Lille Model score
greater than 0.45, calculated after seven days of treatment with
prednisolone, means failure to respond to treatment and predicts
a six-month mortality of about 75% (Lefkowitch 2005).
Description of the intervention
Glucocorticosteroids are used as anti-inflammatory drugs. They
are also known as glucocorticoids, corticosteroids, or steroids.
Glucocorticosteroid agentsmimic the endogenous glucocorticoid,
cortisol (Rhen 2005). Glucocorticosteroids, primarily regulated
by corticotropin, are considered to have anti-inflammatory effects
as well as metabolic and immunogenic effects in the body, by
blocking the infiltration of the white blood cells in the liver tis-
sue. (Rhen 2005). It is agreed that the anti-inflammatory effect of
glucocorticosteroids are mediated primarily through repression of
gene transcription (Schäcke 2002).
How the intervention might work
Glucocorticosteroids administered to people with alcoholic hep-
atitis repair the liver injury by decreasing the liver polymorphonu-
clear neutrophils (effector cells) infiltrates and the level of pro-
inflammatory mediators such as tumour necrosis factor-alpha, in-
tercellular adhesion molecule 1, interleukin-6, and interleukin-
8 in the liver tissue (Taïeb 2000; Spahr 2001). The benefits of
corticosteroids ensue from short-term vascular changes (Schäcke
2002). However, adverse events have still been poorly reported.
Why it is important to do this review
The benefits and harms of corticosteroids for people with alcoholic
hepatitis have been studied extensively in a number of randomised
clinical trials in order to determine the best route of administra-
tion, dose, and duration. However, results have been contradic-
tory. So far, we have found six published meta-analyses with ran-
domised clinical trials (Reynolds 1989; Imperiale 1990; Daures
1991; Christensen 1995; Rambaldi 2008; Mathurin 2011). The
various conclusions regarding patient-oriented outcomes were ex-
plained by the review authors with differences in glucocorticos-
teroid regimens, trial quality, participants’ characteristics, and clin-
ical spectrum of the disease. Reynolds 1989 concluded that cor-
ticosteroid treatment could help only the most severely ill peo-
ple with severe alcoholic hepatitis characterised by high levels of
serum bilirubin, prolonged prothrombin times, and development
of hepatic encephalopathy. Imperiale 1990 concluded that glu-
cocorticosteroids reduced short-term mortality in people with se-
vere alcoholic hepatitis provided that they also had hepatic en-
cephalopathy but did not have severe gastrointestinal bleeding.
Daures 1991 concluded that further randomised clinical trialswere
needed to confirm the benefits and harms of glucocorticosteroids,
especially in people with severe alcoholic hepatitis. Christensen
1995 could not find sufficient proof supporting the routine use of
glucocorticosteroids in people with alcoholic hepatitis, including
people with hepatic encephalopathy. Rambaldi 2008 concluded
that glucocorticosteroids did not improve overall survival in peo-
ple with alcoholic hepatitis. Based on the Trial Sequential Analy-
sis of the subgroup of people with Maddrey’s score of at least 32
or spontaneous hepatic encephalopathy, the required information
size of 2420 people for the outcomemortality was far from reached
with only 249 participants randomised in the six randomised
trials (Rambaldi 2008). Using the Lille model, Mathurin 2011
concluded that glucocorticosteroids significantly improved 28-day
survival in people with severe alcoholic hepatitis. The Mathurin
2011 meta-analysis was based on individual data from five ran-
domised clinical trials. This is why we decided to conduct this
Cochrane systematic review in order to assess the efficacy of gluco-
corticosteroids in people with alcoholic hepatitis with or without
complications.
O B J E C T I V E S
To assess the benefits and harms of glucocorticosteroids in people
with alcoholic hepatitis.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised clinical trials in which glucocorticos-
teroids have been assessed in people with alcoholic hepatitis, irre-
spective of year of publication or language. We will also include
randomised clinical trials reported in an abstract form.
We will include quasi-randomised studies and observational stud-
ies identified during our searches for the assessment of harms.
Types of participants
Wewill include adults with alcoholic hepatitis, according to the di-
agnostic work-up used in the individual randomised clinical trial.
We will consider alcoholic hepatitis as mild if randomised partic-
ipants had jaundice for less than three months, Maddrey’s score
was 32 or less, bilirubin level was less than 50 µmol/L, and the
person was an active drinker.
We will consider alcoholic hepatitis as severe at any stage of the al-
coholic liver disease with the presence of spontaneous hepatic en-
cephalopathy, or Maddrey’s score higher than 32 (Maddrey’s score
= 4.6 x prothrombin time (seconds) + serum bilirubin (milligrams
per decilitre)) (Maddrey 1978). We will consider trials published
before or after 1989 carefully, as theMaddrey’s score was modified
in 1989 in order to stratify severe alcoholic hepatitis and define
the group of people to be treated.
Included trial participants diagnosed with severe alcoholic hep-
atitis may also manifest with hepatic encephalopathy, gastroin-
testinal bleeding, cirrhosis (e.g., classified with Child-Pugh score -
Child-Pugh type C (Pugh 1973)), ascites, hepatorenal syndrome,
hyponatraemia, and spontaneous bacterial peritonitis.
Types of interventions
Glucocorticosteroids administered by any route, dose, and dura-
tion versus placebo or no intervention.
Wewill allow co-interventions provided they donot differ between
intervention and control groups.
Types of outcome measures
Primary outcomes
• All-cause mortality.
• Health-related quality of life (any valid continuous
outcome scale as defined by the trial authors).
• Serious adverse events during treatment. We will use the
International Conference on Harmonisation (ICH) Guidelines
for Good Clinical Practice’s definition of a serious adverse event
(ICH-GCP 1997), that is, any untoward medical occurrence
that results in death, is life threatening, requires hospitalisation
or prolongation of existing hospitalisation, results in persistent or
significant disability or incapacity, or is a congenital anomaly or
birth defect. We will consider all other adverse events as non-
serious (see Secondary outcomes).
Secondary outcomes
• Alcohol liver-related mortality.
• Proportion of participants with one or more of the
following complications: ascites, hepatorenal syndrome,
spontaneous bacterial peritonitis, gastrointestinal bleeding,
hepatic encephalopathy, non-obstructive jaundice, systemic
inflammatory response syndrome, sepsis, or hepatocellular
carcinoma.
• Proportion of people with non-serious adverse events
according to type.
Exploratory outcomes
• Proportion of participants with an increase of liver enzymes
as defined by the trialists.
• Proportion of participants with a decrease of prothrombin
index as defined by the trialists.
• Proportion of participants with a decrease of serum
albumin as defined by the trialists.
We plan to collect data at ’up to three months’ follow-up’ for all
the outcomes, as it has been shown that survival of people with
alcoholic hepatitis will mainly rely on their abstinence beyond that
time point (see Background). In addition, glucocorticosteroids
may have short-term effects. By making ’up to three months’ our
primary time point, we will be unlikely to be mixing outcomes
such as deaths because of alcoholic hepatitis, because of cirrhosis,
and because of recidivism of alcoholism. In addition, we will also
assess the effects of glucocorticosteroids onmaximal follow-up, but
outcomes at this time point may be confounded (Thursz 2015).
Search methods for identification of studies
Electronic searches
We will search The Cochrane Hepato-Biliary Group Controlled
Trials Register (Gluud 2016), Cochrane Central Register of Con-
trolled Trials (CENTRAL), MEDLINE (OvidSP), EMBASE
(OvidSP), Science Citation Index Expanded (Web of Science)
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(Royle 2003), and LILACS (Castro 1997). We will apply no lan-
guage or document type restrictions. Appendix 1 shows the pre-
liminary search strategies with the expected time spans of the
searches.
Searching other resources
We will identify additional references by handsearching the refer-
ence lists of articles from the computerised databases and relevant
review articles.
We will search online trial registries such as clinicaltrials.gov, Eu-
ropean Medicines Agency (www.ema.europa.eu), World Health
Organization International Clinical Trial Registry Platform (
www.who.int/ictrp), the Food and Drug Administration (
www.fda.gov), and pharmaceutical company sources for ongoing
or unpublished trials.
Data collection and analysis
We will follow the available guidelines provided in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
and the Cochrane Hepato-Biliary Group Module (Gluud 2016).
We will perform the analyses using Review Manager 5 (RevMan
2014) and Trial Sequential Analysis (Thorlund 2011; TSA 2011).
We will assess the evidence according to Jakobsen and colleagues
(Jakobsen 2014).
Selection of studies
We will retrieve publications that we consider to be potentially
eligible for inclusion after reading their abstracts, and review ar-
ticles that may provide useful references for studies. Three review
authors (CP, DV, MT) will independently review publications for
eligibility. They will assess each publication to determine if trial
participants and the interventions administered meet the inclu-
sion criteria. We will only include abstracts if sufficient data are
provided for analysis. We will resolve disagreements by discussion
or using any of the remaining authors for arbitration.
Data extraction and management
Three review authors (CP, DV, MT) will independently complete
a data extraction form for all included studies. They will extract
general information on the trial such as publication title; place
and year of publication; trial design; inclusion and exclusion cri-
teria; preliminary sample size calculation reached or not; number
of participants randomised in each trial and following treatment
allocation; diagnostic work-up; age (mean or median); sex or sex
ratio; race; co-infection; type, dose, and route of administration
of glucocorticosteroids and their possible link with adverse events;
concurrent medications used; length of trial; and length of follow-
up. They will insure that they have retrieved all possible data re-
quired for measuring the outcomes of this protocol. The authors
will resolve disagreements by discussion or using any of the re-
maining authors for arbitration.
The three authors will also extract data on malnutrition, if mal-
nutrition is clearly defined by the trial authors. We will use the
extracted information for discussion only.
Assessment of risk of bias in included studies
Three review authors (CP, DV, MT) will independently assess the
risk of bias of each included trial according to the recommen-
dations in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011), the Cochrane Hepato-Biliary Group
Module (Gluud 2015), and methodological studies (Schulz 1995;
Moher 1998; Kjaergard 2001; Wood 2008; Lundh 2012; Savovi
2012a; Savovi 2012b). We will use the following definitions in
the assessment of risk of bias.
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice were adequate if performed by an independent person not
otherwise involved in the trial.
• Unclear risk of bias: the method of sequence generation was
not specified.
• High risk of bias: the sequence generation method was not
random. We will include such studies only for assessments of
harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g.,
if the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants. We
will include such studies only for assessments of harms.
Blinding of participants and personnel
• Low risk of bias: it was mentioned that both participants
and personnel providing the interventions were blinded, and the
method of blinding was described, so that knowledge of
allocation was prevented during the trial.
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• Unclear risk of bias: it was not mentioned if the trial was
blinded, or the trial was described as blinded, but the method or
extent of blinding was not described, so that knowledge of
allocation was possible during the trial.
• High risk of bias: the trial was not blinded, so that the
allocation was known during the trial.
Blinded outcome assessment
• Low risk of bias: it was mentioned that both participants
and personnel providing the interventions were blinded, and the
method of blinding was described, so that knowledge of
allocation was prevented during the trial.
• Unclear risk of bias: it was not mentioned if the trial was
blinded, or the trial was described as blinded, but the method or
extent of blinding was not described, so that knowledge of
allocation was possible during the trial.
• High risk of bias: the trial was not blinded, so that the
allocation was known during the trial.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, were employed to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following pre-defined
outcomes: all-cause mortality, serious adverse events, and alcohol
liver-related mortality. If the original trial protocol was available,
the outcomes should be those called for in that protocol. If the
trial protocol was obtained from a trial registry (e.g.,
clinicaltrials.gov), the outcomes sought should have been those
enumerated in the original protocol if the trial protocol was
registered before or at the time that the trial was begun. If the
trial protocol was registered after the trial was begun, those
outcomes will not be considered to be reliable.
• Unclear risk of bias: not all pre-defined outcomes were
reported fully, or it was unclear whether data on these outcomes
were recorded or not.
• High risk of bias: one or more pre-defined outcomes were
not reported.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conductance, or analyses of results of
the trial.
• Unclear risk of bias: the trial may or may not be free of for-
profit bias as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other bias
domains (e.g. academic bias or authors had conducted trials on
the same topic) that could put it at risk of bias.
• Unclear risk of bias: the trial may or may not have been free
of other domains that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias.
We will classify each trial as having a low, unclear, or high risk of
bias based on the definitions described above. We will include a
bias risk assessment combining all domains and categorise trials
as low risk of bias if none of the domains are classed as high or
unclear risk of bias. Moreover, we will consider trials with one or
more domains with unclear or high risk of bias as trials with high
risks of bias.
We will assess the domains ’Blinding of outcome assessment’, ’In-
complete outcome data’, and ’Selective outcome reporting’ for
each outcome result. Thus, we will be able to assessed the bias risk
for each outcome result in addition for each trial (overall risk of
bias of each trial). We will base our primary conclusions on the
outcome results of our primary outcomes with low risk of bias.
Measures of treatment effect
Dichotomous outcomes
We will use risk ratios (RR) with 95% confidence intervals (CI)
for dichotomous outcomes.
Continuous outcomes
We will use mean difference (MD) with 95% CI for continuous
outcomes. We will use the standardised mean difference (SMD)
with 95%CI for continuous outcomes only if the included studies
use different scales for quality of life.
Unit of analysis issues
The single participant, randomised in the trial.
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Dealing with missing data
If dichotomous or continuous data are missing in a published re-
port, we will, whenever possible, contact the original investigators
to request the missing data.
If trialists used intention-to-treat analysis to deal with missing
data, we will use these data in our primary analysis. If required
data for intention-to-treat analysis are missing, we may not be able
to perform such an analysis.
Dealing with missing data using sensitivity analysis
We will include missing data by considering participants as treat-
ment failures or treatment successes by imputing them according
to the following two scenarios:
• extreme-case analysis favouring the experimental
intervention (’best-worse’ case scenario): none of the participants
who dropped out from the experimental group experienced the
outcome, but all of the participants who dropped out from the
control group experienced the outcome; including all
randomised participants in the denominator.
• extreme-case analysis favouring the control (’worst-best’
case scenario): all participants who dropped out from the
experimental group, but none from the control group
experienced the outcome; including all randomised participants
in the denominator.
For continuous outcomes, in our case quality of life, we will per-
form a ’best-worst’ case scenario analysis assuming that all par-
ticipants lost to follow-up in the experimental group had an im-
proved outcome (the groupmean plus 1 standard deviation (SD));
and all participants with missing outcomes in the control group
had a worsened outcome (the group mean minus 1 SD) (Jakobsen
2014). We will also perform a ’worst-best’ case scenario analysis
assuming that all participants lost to follow-up in the experimental
group had a worsened outcome (the group mean minus 1 SD);
and all participants with missing outcomes in the control group
had an improved outcome (the group mean plus 1 SD) (Jakobsen
2014).
We will perform the two sensitivity scenario analyses only for our
primary outcomes. We will present the results of both scenarios in
our review.
Assessment of heterogeneity
We will address the presence of heterogeneity in both clinical and
statistical ways.
We will assess heterogeneity by visual inspection of the forest plots.
To assess heterogeneity between the trials formerly, we will specif-
ically examine the degree of heterogeneity observed in the results
using the I2 statistic (Higgins 2002). As thresholds for the in-
terpretation of the I2 statistic can be misleading, we will use the
following approximate guide for interpretation of heterogeneity
provided in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity*;
• 50% to 90%: may represent substantial heterogeneity*;
• 75% to 100%: considerable heterogeneity*.
*The importance of the observed value of the I2 statistic depends
on the magnitude and direction of effects and the strength of
evidence for heterogeneity (e.g., P value from the Chi2 test, or a
CI for the I2 statistic).
For the heterogeneity adjustment of the required information size
in the Trial Sequential Analysis, we will use diversity (D2) because
the I2 statistics used for this purpose consistently underestimate
the required information size (Wetterslev 2009).
Depending on the number of eligible trials, we will add co-vari-
ates that may explain heterogeneity to a meta-regression model to
adjust for heterogeneity.
Assessment of reporting biases
If we include 10 or more trials, we will draw funnel plots to assess
reporting biases from the individual trials by plotting the RR on a
logarithmic scale against its standard error (Egger 1997; Higgins
2011).
For dichotomous outcomes, wewill test asymmetry using theHar-
bord test in cases where tau2 is less than 0.1 (Harbord 2006), and
we will use Rücker 2008 in cases where tau2 is more than 0.1. For
continuous outcomes, we will use the regression asymmetry test
(Egger 1997), and the adjusted rank correlation (Begg 1994).
Data synthesis
Meta-analysis
We will perform the meta-analyses using Review Manager 5 (
RevMan 2014), and according to the recommendations stated
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
We will present the results of dichotomous outcomes of individ-
ual trials as RR with 95% CI and the results of the continuous
outcomes as MD with 95% CI.
Assessment of significance
We will perform the meta-analyses using Review Manager 5
(RevMan 2014). We will present the results of dichotomous out-
comes of individual trials as RR with 95% CI and the results of
the continuous outcomes as MD with 95% CI. We will apply
both fixed-effectmodel (DeMets 1987) and random-effects model
(DerSimonian 1986) meta-analyses. If there are statistically sig-
nificant discrepancies in the results (e.g., one giving a significant
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intervention effect and the other no significant intervention ef-
fect), we will report the more conservative point estimate of the
two (Jakobsen 2014). The more conservative point estimate is the
estimate closest to zero effect. If the two point estimates are equal,
we will use the estimate with the widest CI as our main result of
the two analyses. We will consider a P value of 0.025 or less, two-
tailed, as statistically significant if the required information size
is reached due to the three primary outcomes (Jakobsen 2014).
We will use the eight-step procedure to assess if the thresholds for
significance are crossed (Jakobsen 2014). We will present hetero-
geneity using the I2 statistic (Higgins 2002). We will present the
results of the individual trials and meta-analyses in the form of
forest plots.
Where data are only available from one trial, we will use Fisher’s
exact test for dichotomous data (Fisher 1922), and Student’s t-
test for continuous data (Student 1908), to present the results in
a narrative way.
Trial Sequential Analysis
We will apply Trial Sequential Analysis for both dichotomous and
continuous outcomes (Thorlund 2011; TSA 2011), as cumulative
meta-analyses are at risk of producing random errors due to sparse
data and repetitive testing of the accumulating data (Wetterslev
2008). To control random errors, we will calculate the diversity-
adjusted required information size (DARIS) (i.e., the number of
participants needed in a meta-analysis to detect or reject a certain
intervention effect) (Brok 2008; Wetterslev 2008; Brok 2009;
Thorlund 2010).
In our meta-analysis, we will base the DARIS for dichotomous
outcomes on the event proportion in the control group; assump-
tion of a plausible relative risk reduction of 20% of the risk ob-
served in the included trials with low risk of bias; a risk of type I
error of 2.5% due to three primary outcomes (Jakobsen 2014), a
risk of type II error of 20%, and the diversity of the included trials
in the meta-analysis. For quality of life, we will estimate DARIS
using a minimal relevant difference of 10% of the mean response
observed in the control group; the SD; alpha of 2.5% due to the
primary outcomes (Jakobsen 2014); beta of 20%; and the diver-
sity as estimated from the trials in the meta-analysis (Wetterslev
2009). We will also calculate and report the Trial Sequential Anal-
ysis adjusted 95% CI (Thorlund 2011).
The underlying assumption of Trial Sequential Analysis is that
testing for statistical significance may be performed each time a
new trial is added to the meta-analysis. We will add the trials ac-
cording to the year of publication, and, if more than one trial has
been published in a year, we will add trials alphabetically according
to the last name of the first author. On the basis of the DARIS, we
will construct the trial sequential monitoring boundaries for ben-
efit, harm, and futility (Wetterslev 2008; Thorlund 2011). These
boundaries will determine the statistical inference one may draw
regarding the cumulative meta-analysis that has not reached the
DARIS; if the trial sequential monitoring boundary for benefit or
harm is crossed before the DARIS is reached, firm evidence may
be established and further trials may be superfluous. However, if
the boundaries are not crossed, it is most probably necessary to
continue doing trials in order to detect or reject a certain inter-
vention effect. However, if the cumulative Z-curve crosses the trial
sequential monitoring boundaries for futility, no more trials may
be needed.
A more detailed description of Trial Sequential Analysis can be
found at www.ctu.dk/tsa/ (Thorlund 2011).
Subgroup analysis and investigation of heterogeneity
Whenever possible, we will perform the following subgroup anal-
yses.
• Trials with low risk of bias compared to trials with high risk
of bias.
• Trials with participants with mild alcoholic hepatitis
compared to trials with severe alcoholic hepatitis, following the
Maddrey’s score of 32 or lower or higher than 32, or another
score used.
• Trials with dose of the glucocorticosteroid 40 mg or less
compared to trials with dose of the glucocorticosteroid more
than 40 mg.
• Trials with people with severe hepatic hepatitis without
cirrhosis compared to trials with people with severe alcoholic
hepatitis with cirrhosis. If cirrhosis is classified by Child-Pugh
score, then we may be able to perform additional subgroup
analyses in order to adjust for the clinical spectrum of the disease.
• Trials with people with severe alcoholic hepatitis without
hepatorenal syndrome compared to trials with people with severe
alcoholic hepatitis with hepatorenal syndrome.
• Trials with people with severe alcoholic hepatitis without
ascites compared to trials with people with severe alcoholic
hepatitis with ascites.
Additional subgroup analyses maybe considered at the review
stage. Due to the large number of subgroup analyses, we will in-
terpret them conservatively.
Sensitivity analysis
To assess the robustness of the eligibility criteria, in addition to the
sensitivity analyses specified under Dealing with missing data, we
will undertake sensitivity analyses that may explain our findings
as well as any observed heterogeneity.
’Summary of findings’ tables
We will create ’Summary of findings’ tables on all review
outcomes using GRADEpro (tech.cochrane.org/revman/other-
resources/gradepro). The GRADE approach appraises the quality
of a body of evidence based on the extent to which one can be
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confident that an estimate of effect or association reflects the item
being assessed. The quality of a body of evidence considers within-
study risk of bias, indirectness of the evidence, heterogeneity of
the data, imprecision of effect estimates (wide CIs and as evalu-
ated with our Trial Sequential Analyses) (Jakobsen 2014), and risk
of publication bias (Guyatt 2008; Balshem 2011; Guyatt 2011a;
Guyatt 2011b; Guyatt 2011c; Guyatt 2011d; Guyatt 2011e;
Guyatt 2011f; Guyatt 2011g; Guyatt 2011h; Guyatt 2013a;
Guyatt 2013b; Guyatt 2013c; Mustafa 2013).
We will define the levels of evidence as ’high’, ’moderate’, ’low’, or
’very low’. These grades are defined as follows.
• High certainty: this research provides a very good
indication of the likely effect; the likelihood that the effect will
be substantially different is low.
• Moderate certainty: this research provides a good indication
of the likely effect; the likelihood that the effect will be
substantially different is moderate.
• Low certainty: this research provides some indication of the
likely effect; however, the likelihood that it will be substantially
different is high.
• Very low certainty: this research does not provide a reliable
indication of the likely effect; the likelihood that the effect will
be substantially different is very high.
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A P P E N D I C E S
Appendix 1. Search strategies
Database Search performed Search strategy
CochraneHepato-BiliaryControlledTrials
Register
At the review stage. (glucocortico* or steroid* or dexamethasone or prednis* or hy-
drocortisone or corticosteroid* or cortiso* or budesonide* or be-
clomethasone*) AND (alcohol* and (liver or hepati*))
Cochrane Central Register of Controlled
Trials (CENTRAL) (Wiley)
At the review stage. #1MeSHdescriptor: [AdrenalCortexHormones] explode all trees
#2 (glucocortico* or steroid* or dexamethasone or prednis* or
hydrocortisone or corticosteroid* or cortiso* or budesonide* or
beclomethasone*)
#3 #1 or #2
#4 MeSH descriptor: [Hepatitis, Alcoholic] explode all trees
#5 (alcohol* and (liver or hepati*))
#6 #4 or #5
#7 #3 and #6
MEDLINE (OvidSP) At the review stage. 1. exp Adrenal Cortex Hormones/
2. (glucocortico* or steroid* or dexamethasone or prednis* or
hydrocortisone or corticosteroid* or cortiso* or budesonide* or
beclomethasone*).mp. [mp=title, abstract, original title, name of
substance word, subject heading word, keyword heading word,
protocol supplementary conceptword, rare disease supplementary
concept word, unique identifier]
3. 1 or 2
4. exp Hepatitis, Alcoholic/
5. (alcohol* and (liver or hepati*)).mp. [mp=title, abstract, original
title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier]
6. 4 or 5
7. 3 and 6
8. (random* or blind* or placebo* ormeta-analys*).mp. [mp=title,
abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier]
9. 7 and 8
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(Continued)
EMBASE (OvidSP) At the review stage. 1. exp corticosteroid/
2. (glucocortico* or steroid* or dexamethasone or prednis* or hy-
drocortisone or corticosteroid* or cortiso* or budesonide* or be-
clomethasone*).mp. [mp=title, abstract, headingword, drug trade
name, original title, device manufacturer, drug manufacturer, de-
vice trade name, keyword]
3. 1 or 2
4. exp alcohol liver disease/
5. (alcohol* and (liver or hepati*)).mp. [mp=title, abstract, head-
ing word, drug trade name, original title, device manufacturer,
drug manufacturer, device trade name, keyword]
6. 4 or 5
7. 3 and 6
8. (random* or blind* or placebo* or meta-analys*).mp. [mp=
title, abstract, headingword, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword]
9. 7 and 8
Science Citation Index Expanded (Web of
Science)
At the review stage. #5 #4 AND #3
#4 TS=(random* or blind* or placebo* or meta-analys*)
#3 #2 AND #1
#2 TS=(alcohol* and (liver or hepati*))
#1 TS=(glucocortico* or steroid* or dexamethasone or prednis*
or hydrocortisone or corticosteroid* or cortiso* or budesonide*
or beclomethasone*)
WH A T ’ S N E W
Last assessed as up-to-date: 9 June 2016.
Date Event Description
9 June 2016 New citation required and major changes This protocol is a major update of a withdrawn review protocol by
Saconato et al (Saconato 1999)
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N O T E S
Cochrane Reviews can be expected to have a high percentage of overlap in the methods section because of standardised methods. In
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